Triple
T19157077
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | MRK |
E468952
|
entity |
| Predicate | issuerMajorProduct |
P64617
|
FINISHED |
| Object | Keytruda |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Keytruda | Statement: [MRK, issuerMajorProduct, Keytruda]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Keytruda Context triple: [MRK, issuerMajorProduct, Keytruda]
-
A.
Keytruda
chosen
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
B.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
nivolumab
Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
-
E.
Seagen
Seagen is a biotechnology company specializing in the development of antibody-drug conjugate (ADC) therapies for cancer treatment.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: issuerMajorProduct Context triple: [MRK, issuerMajorProduct, Keytruda]
-
A.
issuerType
Indicates the classification or category of the entity that issues something (such as a document, credential, or instrument).
-
B.
issuerMainPlatform
Indicates that an entity serves as the primary platform or main environment through which an issuer operates, offers, or manages its services or instruments.
-
C.
issuerProduces
Indicates that an issuer creates, generates, or brings into existence a particular product, document, asset, or item.
-
D.
issuerSpecialization
Indicates the particular field, domain, or area of expertise in which the issuer is specialized.
-
E.
issuerBrandPortfolioIncludes
chosen
Indicates that an issuer’s overall brand portfolio contains or encompasses a particular brand.
- F. None of above.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8dd084ff48190ac0f8c46ee722629 |
completed | April 10, 2026, 11:20 a.m. |
| NER | Named-entity recognition | batch_69e5eeb9cf9081908b17073755e83554 |
completed | April 20, 2026, 9:15 a.m. |
| PD | Predicate disambiguation | batch_69e4b9b83d6881908e6271c620f74100 |
completed | April 19, 2026, 11:17 a.m. |
Created at: April 10, 2026, 12:06 p.m.